Attached files
| file | filename |
|---|---|
| 8-K - 8-K - CRYOLIFE INC | cryolife8k20210.htm |
| EX-99.1 - PRESS RELEASE - CRYOLIFE INC | cryolife8k20210ex991.htm |
EXHIBIT
99.2
ADDITIONAL IMPORTANT
INFORMATION
This document is
provided for informational purposes only and is not an offer to purchase nor a
solicitation of an offer to sell shares of Medafor or
CryoLife. Subject to future developments, CryoLife may file a
registration statement and/or tender offer documents and/or proxy statement with
the SEC in connection with the proposed combination. Shareholders
should read those filings, and any other filings made by CryoLife with the SEC
in connection with the combination, as they will contain important
information. Those documents, if and when filed, as well as
CryoLife’s other public filings with the SEC, may be obtained without charge at
the SEC’s website at www.sec.gov and at CryoLife’s website at
www.cryolife.com.
Website
FAQ
Why
is CryoLife acquiring a stake in Medafor?
We have
acquired this significant stake in Medafor as a first step in our efforts to
acquire full control of HemoStase and Medafor’s hemostatic
technology. We are taking this step in order to help HemoStase and
related products realize their full potential. If we are successful,
we believe that our experienced management team, strong direct sales force,
international distribution network, and financial strength will allow us to
drive additional growth of HemoStase and related products, and create value for
CryoLife and Medafor shareholders. In the event we are unable to
acquire control of Medafor in the near term, we believe we will be able to
recover the value of this investment in the future.
How
much of Medafor does CryoLife now own?
CryoLife
believes it owns approximately 11 percent of the outstanding Medafor common
stock and that it is now the largest single shareholder of Medafor, in addition
to being Medafor’s largest distributor.
What
are the terms of the proposal CryoLife made most recently to
Medafor?
On
January 13, 2010, CryoLife sent a letter to Medafor’s management and board
requesting to enter into discussions with them regarding a potential acquisition
by CryoLife of the remaining outstanding common stock of Medafor for $2.00 per
share in a combination of cash and CryoLife stock, subject to completion of
reasonable due diligence. This would provide Medafor shareholders
with certain value through a cash component, as well as the opportunity to
participate in future upside through continued ownership of the combined company
under CryoLife leadership.
We
believe this proposal to Medafor represents full and fair value, reflecting both
the upside from the growth potential of HemoStase and the product’s underlying
technology, as well as the downside presented by the IP restrictions on this
product.
Our
proposal also represents a significant premium to the price at which we believe
Medafor’s own board and management have recently offered to convert debt into
equity.
What
is the breakdown between cash and stock?
Negotiations
with the Medafor board would allow us to determine the right mix of cash and
stock. We believe a cash/stock offer is appropriate and attractive,
as the cash component would provide Medafor shareholders with immediate and
certain value, while the stock portion would allow shareholders to participate
in future upside through continued ownership of the combined
company. We think the prospects for CryoLife are strong and that
Medafor shareholders will be able to realize additional value by owning our
stock. It is also important to note that ownership of CryoLife stock
would provide shareholders with further liquidity, as they would be able to
trade this stock on the New York Stock Exchange. That said, given the
current economic climate, we recognize that cash may be more important to some
shareholders, and we are therefore prepared to evaluate how this is best
addressed.
What
has been the reaction of Medafor’s board to the recent CryoLife
proposal?
CryoLife
received a letter from Medafor’s board on January 22, 2010 that stated that
Medafor’s board was considering its options. CryoLife has not heard
from Medafor’s board since that communication. CryoLife remains
committed to entering into friendly negotiations with Medafor’s board and
management, but, in the event that Medafor’s board continues to delay, we may
consider additional actions to facilitate a transaction with Medafor that would
not require the approval of current board members.
Why
did CryoLife choose to make this proposal public?
CryoLife
has made every effort to work with Medafor as partners in an amicable and
productive manner. We have made numerous attempts to engage with
Medafor’s management and board about a potential value-creating acquisition of
the company by CryoLife. Prior to Medafor’s most recent communication
asking us for additional time, Medafor had summarily rejected all of our
overtures and refused to negotiate with us. By providing our fellow
Medafor shareholders with complete and timely information about our proposal, we
hope to encourage Medafor’s management and board to come to the
table.
Is
the proposal made to the Medafor board available to Medafor
shareholders?
Not at
this time. It is our hope that by making our proposal public, we will
encourage Medafor’s management and board to engage in discussions with us, or at
least remove any legal barriers that would prevent us from purchasing additional
shares from Medafor shareholders.
What
can Medafor shareholders who wish to sell their shares to CryoLife
do?
We
encourage shareholders to make their voices heard to Medafor’s management and
board by contacting them directly.
Why
is CryoLife purchasing additional shares from some investors but not making its
proposal available to all?
We have
purchased some additional shares from Medafor shareholders in order to bring our
holding to over 10 percent and to obtain the additional right of being able to
call a special shareholders meeting. At this time, we remain hopeful
that we can engage in friendly negotiations with Medafor’s board about our
proposal. While we may make some additional purchases of Medafor
stock from time to time, we encourage shareholders to make their voices heard to
Medafor’s management and board by contacting them directly. If
Medafor’s board refuses to enter into negotiations with us, we will consider our
other options.
How
does CryoLife intend to effect an acquisition of Medafor without agreement from
their management/board if Medafor refuses to negotiate?
It is our
hope that having demonstrated our commitment to a value-creating transaction by
publicly announcing our proposal, Medafor’s management and board will agree to
engage in discussions with us. Further, we believe that as a
substantial shareholder of Medafor, we have a right to a voice in Medafor’s
management, and we will exercise that right to its fullest potential in order to
remove any impediments that currently block Medafor shareholders from being able
to sell their shares to us. If necessary, we may consider additional
actions to facilitate a transaction with Medafor that would not require the
approval of current board members.
Why
should Medafor sell itself to CryoLife?
Medafor
needs to accelerate its rollout of HemoStase and the underlying hemostatic
technology. Such a rollout inherently requires a significant outlay
of capital. We think CryoLife can facilitate this rollout in a way
that would prevent the need for repeatedly accessing traditional equity
markets. Accessing equity markets will likely produce unnecessary
further dilution for Medafor’s current shareholders. We note that
current management has increased outstanding shares by more than 13 million
shares since 2005 (at that time there were only 7.7 million shares outstanding),
and has not been able to generate an exit strategy that provides value to
existing Medafor shareholders. At the same time, as Medafor’s largest
distributor, we feel that integrating our two companies would produce the
greatest revenue growth and profitability for this technology, and increase
returns for both Medafor and CryoLife shareholders.
How
has Medafor failed to help HemoStase reach its full potential? What
will CryoLife do differently?
Medafor
has failed to maximize the potential of HemoStase and the product’s underlying
technology for its shareholders. Medafor’s capital constraints
prevent it from conducting significant research and development and investing in
its sales force and distribution network in a meaningful way. With
significantly greater resources, CryoLife would remedy this.
Our
management team has over 150 years combined experience in the medical device
business. We have a direct sales force in the U.S. and an
international distribution network comprised of both direct employees and third
party representatives who are focused on cardiac, vascular and general
surgeons. HemoStase is a perfect complement to CryoLife’s BioGlue
technology; together BioGlue and HemoStase offer a full range of products to our
surgeon customers to assist them in the control and prevention of
bleeding. We have already demonstrated our ability to sell HemoStase
(having achieved $6 million in sales in 2009) and have the resources available
to us to ensure that HemoStase and related products properly penetrate the
market.
How
did CryoLife come to this current proposal?
The
proposal price results from a detailed analysis of Medafor, its products, and
the market conducted by CryoLife in conjunction with its financial and legal
advisors. The valuation is consistent with comparable company
valuations, similar M&A transactions, and other relevant metrics and
methodologies. We believe our proposal to Medafor represents full and
fair value, reflecting both the upside from the growth potential of HemoStase
and the product’s underlying technology, as well as the downside presented by
the significant IP restrictions on this product. Of course, our
analysis is based upon the best information available to us. We
remain open to negotiating our proposal further with Medafor’s management and
board, and have indicated our desire to enter into discussions and consider
further information about Medafor. Any final offer will be contingent
upon the conclusion of reasonable due diligence.
In the
event that Medafor’s board does not engage in negotiations with us, we plan to
provide additional detail with regard to our valuation of Medafor directly to
shareholders.
Does
CryoLife’s Medafor stake give CryoLife any additional powers outside those of a
normal shareholder?
Minnesota
corporate law gives special rights to persons who own 3% or more of the common
stock in Medafor. Thus, CryoLife has the right to propose amendments
to the Articles of Incorporation or bylaws of Medafor at a regularly scheduled
meeting of shareholders, and if a meeting has not been held during the last 15
months, CryoLife can demand one.
Additionally,
as an owner of more than 10% of Medafor’s outstanding shares, CryoLife has the
right to call a special shareholders meeting pursuant to Medafor’s
bylaws. CryoLife remains committed to entering into friendly
negotiations with Medafor’s board and management, but, in the event that
Medafor’s board continues to delay, a special shareholders meeting would afford
CryoLife the opportunity to seek to replace the Medafor board in order to
maximize value for all Medafor shareholders.
What
are CryoLife’s next steps?
We hope
to begin negotiations with the Medafor board. If necessary, however,
we may consider additional actions to facilitate a transaction with Medafor that
would not require the approval of current board members.
When
does CryoLife plan to communicate with Medafor shareholders?
Outside
of this information, if we are unable to meet with or reach agreement with the
Medafor board in a timely fashion, we plan to continue to communicate with
Medafor shareholders directly about our offer for Medafor and our strategy for
the company going forward.
What
is the timing for this process?
If
Medafor’s board agrees to negotiate with us and we ultimately reach agreement,
we believe this process could take several months. If Medafor’s board
refuses to negotiate with us, then we will evaluate our options.
Who
can shareholders contact if they have questions?
You may
contact Nina Devlin at Edelman at 212-704-8145 for more
information. You may also leave a question at the following email
address medaforinfo@cryolife.com and someone will contact you.
Statements
made in this document that look forward in time or that express management's
beliefs, expectations or hopes are forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements include those regarding future actions we may take with respect to
Medafor, our efforts to acquire full control of HemoStase and Medafor’s
hemostatic technology, our ability to help HemoStase realize its full potential
and drive additional sales of HemoStase and related products, and create value
and increase returns for CryoLife and Medafor shareholders, our belief that we
will be able to recover the value of our investment in Medafor, our plans to
communicate with Medafor shareholders about our offer for Medafor and our
strategy for the company going forward at a future date, and our beliefs
regarding the potential timing of a transaction. These future events
may not occur as and when expected, if at all, and, together with our business,
are subject to various risks and uncertainties. These risks and
uncertainties include that any transaction with Medafor may not occur or may be
delayed due to circumstances and events beyond our control, including legal
impediments, we may not be able to realize the anticipated benefits of a
transaction with Medafor, our plans to acquire Medafor may change, our plans to
communicate publicly regarding the proposed transaction may change and may be
influenced by various legal and regulatory considerations, and Medafor’s
management may act in ways that differ from our current
expectations. The timing of and our ability to communicate with
Medafor shareholders may be impacted by the actions of Medafor
management. Also, the success of any transaction between CryoLife and
Medafor is subject to risks facing both companies. These risks
include that CryoLife is significantly dependent on revenues from BioGlue and
there are a variety of risks affecting BioGlue, CryoValve SG pulmonary heart
valves and other SynerGraft processed tissues and products may not be accepted
by the marketplace, the CryoValve SG pulmonary heart valve has a one year shelf
life, the CryoPatch SG has a one year shelf life, we are dependent on the
availability of sufficient quantities of tissue from human donors, the CryoValve
SG pulmonary heart valve post-clearance study requested by the FDA may not
provide the expected positive results, our products and tissues we process and
preserve have allegedly caused and may in the future cause injury to patients,
and we have been and may be exposed to tissue processing and product liability
claims and additional regulatory scrutiny as a result, the possibility that the
FDA could impose additional restrictions on our operations, issue a 483, or
warning letter, or require a recall, or prevent us from processing and
distributing tissues or manufacturing and distributing other products, our
failure to adequately comply with government regulations could result in loss of
revenues and customers as well as additional compliance expense, our ability to
borrow under our credit facility may be limited, the credit facility limits our
ability to pursue significant acquisitions, the financial and credit liquidity
crisis may adversely affect our ability to borrow money or raise capital, the
current economic crisis and future economic crises may adversely affect our
business and financial condition, there are limitations on our use of net
operating loss carry-forwards that could result in our inability to use them
fully or at all, adverse regulatory action outside of the U.S. could affect our
business, physicians have been and may be reluctant to implant or use our
preserved tissues or products, our existing insurance policies may not be
sufficient to cover our actual claims liability, current economic conditions may
impact demand for our tissues and products, intense competition may affect our
ability to operate profitably, we may be unable to obtain adequate insurance at
a reasonable cost or at all, uncertainties related to patents and protection of
proprietary technology may adversely affect the value of our intellectual
property, uncertainties related to patents and protection of proprietary
technology for products distributed by us may adversely affect our ability to
distribute those products, we are dependent on key personnel, we may not be
successful in obtaining necessary clinical results and regulatory approvals for
products and services in development, and our new products and services may not
achieve market acceptance, we may be unable to effectively leverage our existing
sales force to sell HemoStase, the lawsuit we filed against Medafor regarding
our distribution agreement with Medafor may continue to adversely impact our
relationship with Medafor and could hamper or prevent us from distributing
HemoStase, Medafor may in the future attempt to terminate our distribution
agreement, rapid technological change could cause our services and products to
become obsolete, extensive government regulation may adversely affect our
ability to develop and sell products and services, we have experienced operating
losses and negative cash flows in the past, and we must continue to address the
underlying causes in order to continue to operate profitably and generate
positive cash flows, investments in new technologies and acquisitions of
products or distribution rights may not be successful, if we are not successful
in expanding our business activities in international markets, we will be unable
to pursue one of our strategies for increasing our revenues, continued deflation
of foreign currencies relative to the U.S. dollar could materially and adversely
impact our foreign revenues, and future healthcare policies, healthcare
reimbursement methods, and healthcare reimbursement policies may affect the
availability, amount, and timing of our revenues, financial condition, and
profitability. These risks and uncertainties include the risk factors
detailed in our Securities and Exchange Commission filings, including our Form
10-K filing for the year ended December 31, 2008, our Form 10-Q filing for the
quarter ended March 31, 2009, our Form 10-Q filing for the quarter ended June
30, 2009, our Form 10-Q filing for the quarter ended September 30, 2009, and the
Company's other SEC filings. Medafor’s business is also subject to a
number of risks, including the risk that HemoStase does not have adequate
intellectual property protection, that additional regulatory approvals may not
be obtained in a timely fashion, if at all, and that product liability lawsuits
could be filed in connection with the use of HemoStase. In addition,
the acquisition of Medafor by CryoLife, if it occurs, could result in unexpected
costs or liabilities to CryoLife due to potential non-compliance by Medafor
under applicable laws and regulations, although CryoLife is currently not aware
of any material non-compliance, or due to other factors that we are not
currently able to predict, as we have not had the opportunity to perform a due
diligence review with respect to Medafor. The Company does not
undertake to update its forward-looking statements. In addition, the
calculation of the estimated percentage of Medafor’s outstanding shares owned by
CryoLife is based on 20,950,445 shares outstanding, the number of outstanding
shares shown on Medafor’s shareholder list as updated on January 21,
2010. This calculation does not take into account any shares that may
have been repurchased or issued by Medafor since that date. As a
result, CryoLife’s actual percentage ownership of Medafor’s outstanding common
stock may be greater or less than 11%.